ClinicalTrials.gg
CompletedNCT04871893multiECCO2RUpdated Feb 28, 2025

Safety and Efficacy Evaluation of CO2 Removal in Combination With Continuous Veno-Venous Hemodialysis/Hemodiafiltration Therapy

An interventional study of multiECCO2R blood-gas exchanger in Acute Lung Injury, Acute Kidney Injury and Hypercapnia, sponsored by Fresenius Medical Care Deutschland GmbH. Completed at 6 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Fresenius Medical Care Deutschland GmbH (part of Fresenius Medical Care) · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Objective of the study is to assess the safety and efficacy of CO2 removal by the multiECCO2R (CO2 Removal System) on the multiFiltrate/multiFiltrate Pro in veno-venous extracorporeal circulation during continuous renal replacement therapy (CRRT) in patients presenting with hypercapnia due to acute lung failure and acute kidney injury.

02

Conditions studied

  • Acute Lung Injury
  • Acute Kidney Injury
  • Hypercapnia
  • Covid19

Keywords

  • CO2 removal
  • Continuous Renal Replacement Therapy
  • blood-gas exchanger
  • CRRT
  • multiECCO2R
03

In context

Acute Lung Injury

382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.

This study's enrollment of 28 is below the median of 60 across 227 interventional studies indexed under Acute Lung Injury.

Browse Acute Lung Injury studies →

Lead sponsor

Fresenius Medical Care Deutschland GmbH is the lead sponsor of 36 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed and dated by the investigator; and:

    1. if patient is able to give consent: by the study patient
    2. if patient is unable to give consent: by the legal representative or
    3. if an emergency situation is determined: by an independent consultant physician
  • Minimum age of 18 years

Study-specific:

  • Body weight greater than 40 kg
  • Acute Kidney Injury (AKI) with clinical indication for CRRT
  • Hypercapnia with indication for ECCO2R:

(paCO2 ≥ 55 mmHg at given best possible protective ventilation parameters: Guiding parameters: tidal volume = 6 ml/kg PBW, PEEP to be adjusted according to the FiO2 1, driving pressure \< 15 cmH2O, max. inspiratory pressure \< 30 cmH2O or TV\<=5 ml/kg when max. inspiratory pressure\< 30 cmH2O cannot be held)

  • Vascular access and Shaldon catheter allowing blood flow of 100 ml/min to 500 ml/min
  • Arterial line in place, allowing blood sampling
  • Estimated greater than 3 days

Exclusion criteria

Exclusion Criteria:

  • In case of female patients: pregnancy or lactation period (if patient is ≥ 55 years old or have been surgically sterilized, a negative pregnancy test is not required)
  • Participation in an interventional clinical study during the preceding 72 hours
  • Previous participation in the same study

Study-specific

  • Severe ARDS (Berlin definition): PaO2/FiO2 \< 100 mmHg
  • Intracerebral haemorrhage
  • Intracranial hypertension
  • Acute myocardial infarction
  • to heparin or known history of heparin induced thrombocytopenia (HIT Type II), if heparin is used as anticoagulant
  • severe liver insufficiency or fulminant hepatic failure
  • Uncontrolled bleeding and coagulation disorders, thrombocytopenia \< 75000µL
  • Liver cirrhosis Classification > A
  • > 40 kg/m²
  • Decision to limit therapeutic interventions
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Other
    Treatment with the blood-gas exchanger multiECCO2R for CO2 removal

    Treatment of patients suffering from hypercapnia due to acute lung failure and acute kidney injury (AKI). Patients will be treated up to 72 hours with CVVHD/HDF with a standard multiFiltrate blood line kit (multiFiltrate or multiFiltrate Pro). In order to perform an ECCO2R procedure during CVVHD/HDF treatment, the blood-gas exchanger multiECCO2R is inserted in a specifically designed blood line kit downstream of the hemodialyzer.

    Device: multiECCO2R blood-gas exchanger

Interventions

  • DevicemultiECCO2R blood-gas exchanger

    Treatment with the blood-gas exchanger multiECCO2R for CO2 removal

06

What researchers measure

Primary outcomes

  1. Clinical efficiency variables: Change of PaCO2

    Change of PaCO2 during the first 30 minutes of treatment (Blood-gas analysis (BGA))

    Time frame: 30 minutes after start of treatment

Secondary outcomes

  1. Technical efficiency variables: Change of pCO2

    Change of pCO2 within the extracorporeal circuit by pre- and post- CO2-exchanger during the treatment (Blood-gas analysis (BGA))

    Time frame: 72 hours after start of treatment

07

Study locations

6 sites
  • Universitätsklinikum Erlangen
    Erlangen, Bayern 91054, Germany
  • Universitätsklinikum Regensburg Klinik und Poliklinik für Innere Medizin
    Regensburg, Bayern 93053, Germany
  • Charité - Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Klinikum Donaustauf
    Donaustauf, 93093, Germany
  • Universitätsklinikum Hamburg
    Hamburg, 20246, Germany
  • Klinikum Herford
    Herford, 32049, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Dec 2024, 32 months.

Of 52 interventional studies with no phase under Acute Lung Injury, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
May 4, 2021
StartActual
Mar 25, 2022
Primary completionActual
Dec 6, 2024
CompletionActual
Dec 31, 2024
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04871893
Collaborators
CERES GmbH
Responsible party
Sponsor
First posted
May 4, 2021
Start date
Mar 25, 2022
Primary completion
Dec 6, 2024
Completion
Dec 31, 2024
Last update
Feb 28, 2025

Study contacts

Thomas Müller, Prof. Dr.
study director · Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin
Matthias Lubnow, Dr. med.
principal investigator · Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion